Nucleic Acid, Nucleoside, or Nucleotide
Solbinsiran: Eli Lilly’s Promising ANGPTL3 Inhibitor for Lipid Management
ANGPTL3 inhibition, solbinsiran, dyslipidemia, lipid reduction, siRNA therapy
Lilly’s Lepodisiran Shows Durable Lipoprotein(a) Reduction in Phase 2 Trial
lepodisiran, lipoprotein(a), Lp(a), cardiovascular disease, RNA interference, long-acting therapy
Arbor sails into rocky gene editing waters with $74M for rare liver disease therapy
Gene editing, CRISPR, Rare liver disease, Primary hyperoxaluria type 1 (PH1), Funding
Avidity’s Del-zota Shows Promise in Duchenne Muscular Dystrophy Treatment
Del-zota, Duchenne muscular dystrophy (DMD), RNA therapeutics, exon 44 skipping, dystrophin production, creatine kinase reduction, safety profile
Gilead Faces Legal Challenges Over Alleged HIV Drug Patent Extension Strategy
Product hopping, Patent extension, HIV drugs, Tenofovir, Antitrust, Truvada, TAF vs TDF
Ono Pharmaceutical Acquires Global Rights to Ionis’ Sapablursen for Polycythemia Vera in $940M Deal
Ono Pharmaceutical, Ionis Pharmaceuticals, sapablursen, polycythemia vera, licensing agreement, RNA-targeted medicine
Daiichi turns to Nosis for AI-designed RNA delivery tech
Nosis, Daiichi, RNA, Sankyo, Partnership, Biosciences, Cells, Chronic disease
FDA Pauses BioNTech’s Malaria Vaccine Trial Amid Regulatory Scrutiny
BioNTech, malaria vaccine, FDA clinical hold, RNA vaccine, regulatory challenges
Entrada given go-ahead to test DMD therapy after two-year hold
Entrada, Muscular Dystrophy, Duchenne, DMD, United States Food and Drug Administration, Adult, Exons